RYZ101
Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
Key Facts
About RayzeBio
RayzeBio is a San Diego-based radiopharmaceutical company founded in 2020, specializing in targeted alpha therapies using actinium-225. The company has built a pipeline of drug candidates aimed at various solid tumors and was acquired by Bristol Myers Squibb, indicating strong validation of its platform and pipeline. RayzeBio's approach combines a proprietary targeting moiety with a potent radioactive payload to deliver precise, tumor-killing radiation while aiming to minimize damage to healthy tissues.
View full company profileAbout RayzeBio
RayzeBio is a San Diego-based radiopharmaceutical company founded in 2020, specializing in targeted alpha therapies using actinium-225. The company has built a pipeline of drug candidates aimed at various solid tumors and was acquired by Bristol Myers Squibb, indicating strong validation of its platform and pipeline. RayzeBio's approach combines a proprietary targeting moiety with a potent radioactive payload to deliver precise, tumor-killing radiation while aiming to minimize damage to healthy tissues.
View full company profileTherapeutic Areas
Other Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Drugs
| Drug | Company | Phase |
|---|---|---|
| n.c.a. ¹⁷⁷Lu-edotreotide (ITM-11) | ITM Isotopen Technologien München | Phase 3 |